One of the fastest ways to make money on the stock market is to gamble on short-term contrarian positions against the shorting interest of a stock. Since every company’s proportion of shorted stock is publicly available, it’s pretty easy to see which companies are expected to lose value. However, short positions on stocks are speculative, like any other investment, and can become short-squeeze stocks in the blink of an eye.So, how does a shorted stock become a short squeeze stock? It all depends on an unexp ...

REDWOOD CITY, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea’s ongoing Phase I/II clinical trials of the Company’s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively. The Company will continue ongoing safety and efficacy data colle ...

For those seeking blistering returns in a relatively short amount of time, short-squeeze stocks may be the go-to place. Here, contrarians leverage the power of psychology to the extreme, leading to possibly intense fervor. To recap, a short position starts when a speculator borrows shares of the targeted enterprise from a broker. From there, the trader dumps the securities in the hopes of picking them up later at a discount. The aim is to return the borrowed shares back to the broker and pocket the differen ...

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced the completion of enrollment of the first three dose expansion arms of COVALENT- 111, with a total of over 260 type 2 diabetes patients enrolled. The COVALENT-111 study is a multi-s ...

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced the completion of enrollment of the first three dose expansion arms of COVALENT111, with a total of over 260 type 2 diabetes patients enrolled. The COVALENT-111 study is a multi-sit ...

股市疯狂 - GameStop (NYSE: GME) 和 AMC Entertainment (NYSE: AMC) 股票价值在一天内增长超过100%，引发了股市的疯狂，导致空头卖家损失超过10亿美元，而 GME 和 AMC 股票市值增加了60亿美元以上[1] - AMC Entertainment 和 GameStop 等“迷因股票”在交易中表现出色，市值增加了超过100亿美元[8] 空头持仓 - 有分析指出，股市中存在高比例的空头持仓股票，这些股票很可能成为未来几天的目标，为读者提供了宝贵的见解[3] - Sunpower Corporation (NASDAQ: SPWR)、Children’s Place (NASDAQ: PLCE)、B.Riley Financial (NASDAQ: RILY) 和 Biomea Fusion (NASDAQ: BMEA) 等股票的空头持仓比例超过50%，被认为是短期压力释放的完美目标[4]

Exhibit 99.1 Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights • Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks, supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy, insulin-producing beta cells • Announced initial clinical data from our Phase 2 study (COVALENT-112) in type 1 d ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40335 Biomea Fusion, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-2520134 (State or other jurisdiction ...

REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (NASDAQ:BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on May 1, 2024, the compensation committee of Biomea's board of directors granted 8 new employees non-qualified stock options to purchase an aggregate of 80,250 shares of the Company's c ...

Exhibit 99.1 Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights • In 2023, reported Phase 2 data (COVALENT-111) in type 2 diabetes patients supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy, insulin-producing beta cells. o After just a 4-week treatment period in type 2 diabetes patients, who had previously failed standard of care (HbA1c > 7.0% and < 10%), BMF-219 demonstrated continued glycemic control ...